Opening closed inward rectifier potassium channel doors
British Journal of Pharmacology · 2026-05 · 183 (10) · 2197-2218
DOI: 10.1111/bph.70374 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2026-02-19. Written by Anna Stary-Weinzinger and 3 co-authors. Institution: Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, Vienna, Austria. Major MEDLINE topics: Potassium Channels, Inwardly Rectifying. Cited 5 times so far (Crossref); 153 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Inwardly rectifying potassium (K IR ) channels are essential regulators of membrane potential in excitable and non‐excitable tissues. Although K IR channels exhibit a biophysical preference for potassium influx due to voltage‐dependent block of outward current by polyamines and Mg 2+ , under physiological conditions, they predominantly mediate K + efflux. This outward current not only is essential for stabilizing the resting membrane potential, limiting cellular excitability and coordinating rhythmic activity in excitable tissues such as the heart and muscle, but also functions in endocrine and exocrine organs and neural tissues. A growing list of pathogenic K IR mutations that reduce or abolish channel activity has been linked to channelopathies, including Andersen syndrome and EAST/SeSAME syndrome, among others. These loss‐of‐function phenotypes underscore the therapeutic need for selective K IR channel activators. However, pharmacological tools remain limited and subtype‐selective activation is rare. Small molecules such as ML297 selectively activate K ir 3.1/3.2‐containing channels, whereas GiGA1 and VU0529331 target K ir 3.2‐containing subunits. Several clinically used drugs (e.g. propafenone) modulate K ir 2.1 and novel compounds such as GPV0057 show improved selectivity. However, no K IR channel activators have advanced to clinical trials and key subtypes such as K ir 1.1 and K ir 7.1 lack known openers. This review evaluates the current knowledge of K IR ‐targeted agonists, with a focus on their potential to address PIP 2 ‐dependent loss‐of‐function mutations in K IR channels. We emphasize the urgent need for subtype‐specific K IR openers, the development of PIP 2 ‐independent mechanisms of action and comprehensive preclinical characterization to overcome translational barriers. Addressing these challenges may provide new therapeutic opportunities for rare channelopathies associated with K IR channel dysfunction.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
- Department of Medical Physiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands.
- Université Côte d'Azur, CNRS, LP2M, Nice, France.
ORCID profiles: Anna Stary-Weinzinger, Fabian Kaiser, Marcel A G van der Heyden, Saïd Bendahhou
Cite
APA
Stary-Weinzinger, A., Kaiser, F., van der Heyden, M. A. G., & Bendahhou, S. (2026). Opening closed inward rectifier potassium channel doors. British Journal of Pharmacology, 183(10), 2197-2218. https://doi.org/10.1111/bph.70374
Vancouver
Stary-Weinzinger A, Kaiser F, van der Heyden MAG, Bendahhou S. Opening closed inward rectifier potassium channel doors. British Journal of Pharmacology. 2026;183(10):2197-2218. doi:10.1111/bph.70374
BibTeX
@article{StaryWeinzinger2026,
author = {Stary-Weinzinger, Anna and Kaiser, Fabian and van der Heyden, Marcel A G and Bendahhou, Saïd},
title = {Opening closed inward rectifier potassium channel doors},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {10},
pages = {2197--2218},
doi = {10.1111/bph.70374}
}
EUVIMED